



Open Government Impact Statement

81st Oregon Legislative Assembly
2021 Regular Session

Measure: SB 844 - B

Only impacts on Original or Engrossed
Versions are Considered Official

Prepared by: Cameron D. Miles
Date: 6/25/2021

SUMMARY

Establishes Prescription Drug Affordability Board in Department of Consumer and Business Services to review prices for nine drugs and at least one insulin product, from among drugs reported to Prescription Drug Price Transparency program by prescription drug manufacturers, drugs reported by insurers in filings and insulin drugs marketed in this state, that are expected to create affordability challenges for health systems or high out-of-pocket costs for patients in Oregon based on specified criteria. Requires department, in consultation with board, to establish and assess fees against manufacturers of prescription drug products sold in Oregon for costs of carrying out duties of board.

OPEN GOVERNMENT IMPACT

Legislative Counsel has not adopted standards for drafting measures that establish exemptions from disclosure of public records.

This measure prohibits public disclosure by the Department of Consumer and Business Services and the Prescription Drug Affordability Board of information collected, used or relied on for the board's prescription drug affordability reviews that is submitted by a manufacturer to the department under the Prescription Drug Price Transparency program and is confidential, proprietary or a trade secret under the state's public records request law.

If those public records that could be subject to public disclosure were instead subject to mandatory disclosure under public records law, health care data and information regarding consumers reporting price increases for prescription drugs would more likely be made public.